Alnylam Pharma (DUL) Q3 2023 Earnings Report
DE:DUL Q3 2023 EPS Results
- Actual EPS
- EUR 1.03
- Consensus EPS
- -EUR 1.29
- Beat/Miss
- Beat by +EUR 2.32
- One Year Ago EPS
- -EUR 2.96
DE:DUL Q3 2023 Revenue Results
- Actual Revenue
- EUR 670.11M
- Expected Revenue
- EUR 354.25M
- Beat/Miss
- Beat by +EUR 315.87M
- YoY Revenue Growth
- +183.96%
Earnings Announcement Details
- Quarter
- Q3 2023
- Date
- 11/02/2023
- Time
- Before Open
- Conference Call
- Thursday, November 2, 2023
DE:DUL Upcoming Earnings
Alnylam Pharma's next earnings date is estimated for February 18, 2027, based on past reporting schedules.
Q3 2023 Earnings Call Audio
DE:DUL Q3 2023 Earnings Call
0:00 / 0:00
Q3 2023 Earnings Slide Deck
Q3 2023 Earnings Call Summary
No earnings call summary is available for this earnings event.
DE:DUL Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 18, 2027 | 2026 (Q4) | 1.56- | 0.73 | ― | ― |
| Oct 29, 2026 | 2026 (Q3) | 1.4814.04 | 1.64 | 754.35% (+12.39) | |
| Jul 30, 2026 | 2026 (Q2) | 1.461.08 | -0.46 | 337.25% (+1.54) | |
| Apr 30, 2026 | 2026 (Q1) | 0.781.35 | -0.39 | 443.18% (+1.74) | |
| Feb 12, 2026 | 2025 (Q4) | 1.030.73 | -0.58 | 226.15% (+1.31) | |
| Oct 30, 2025 | 2025 (Q3) | 0.501.64 | -0.78 | 311.49% (+2.42) | |
| Jul 31, 2025 | 2025 (Q2) | -0.49-0.46 | -0.12 | -292.31% (-0.34) | |
| May 01, 2025 | 2025 (Q1) | -0.79-0.39 | -0.46 | 15.38% (+0.07) | |
| Feb 13, 2025 | 2024 (Q4) | -0.53-0.58 | -0.98 | 40.91% (+0.40) | |
| Oct 31, 2024 | 2024 (Q3) | -0.82-0.78 | 1.03 | -175.65% (-1.80) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat Missed
